Provided by Tiger Trade Technology Pte. Ltd.

Oppenheimer

113.94
-2.5000-2.15%
Post-market: 113.940.00000.00%19:30 EDT
Volume:93.06K
Turnover:10.74M
Market Cap:1.22B
PE:12.64
High:116.75
Open:116.57
Low:113.94
Close:116.44
52wk High:125.88
52wk Low:63.81
Shares:10.71M
Float Shares:6.07M
Volume Ratio:0.74
T/O Rate:1.53%
Dividend:0.76
Dividend Rate:0.67%
EPS(TTM):9.01
EPS(LYR):13.04
ROE:10.82%
ROA:2.59%
PB:1.24
PE(LYR):8.74

Loading ...

Oppenheimer Adjusts Pelthos Therapeutics PT to $64 From $66, Maintains Outperform Rating

MT Newswires Live
·
Aug 14

Oppenheimer Remains a Buy on SentinelOne (S)

TIPRANKS
·
Aug 14

Oppenheimer Remains a Buy on Mediwound (MDWD)

TIPRANKS
·
Aug 14

Oppenheimer Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

TIPRANKS
·
Aug 14

Oppenheimer Sticks to Their Buy Rating for Selective Insurance Group (SIGI)

TIPRANKS
·
Aug 14

Oppenheimer Initiates Carriage Services at Outperform With $48 Price Target

MT Newswires Live
·
Aug 14

Oppenheimer Adjusts Elastic Price Target to $100 From $75, Maintains Outperform Rating

MT Newswires Live
·
Aug 13

Oppenheimer Adjusts PT on Crescent Capital BDC to $14 From $16, Maintains Perform Rating

MT Newswires Live
·
Aug 13

Gain Therapeutics (GANX) Gets a Buy from Oppenheimer

TIPRANKS
·
Aug 13

Oppenheimer Sticks to Their Hold Rating for Pliant Therapeutics (PLRX)

TIPRANKS
·
Aug 13

H&R Block (HRB) Receives a Hold from Oppenheimer

TIPRANKS
·
Aug 13

Legend Biotech Shares Fall After Oppenheimer Downgrade

MT Newswires Live
·
Aug 13

Legend Biotech Could See Pressures From Competition, CEO Transition, Oppenheimer Says

MT Newswires Live
·
Aug 12

H&R Indicates 'Similar' Growth for Fiscal 2027, Oppenheimer Says

MT Newswires Live
·
Aug 12

Intuitive Surgical's Competitors Face Challenges That Limit Long-Term Appeal, Oppenheimer Says

MT Newswires Live
·
Aug 12

MongoDB to Post Solid Fiscal Q2 Results on Enterprise Advanced, Atlas Upside, Oppenheimer Says

MT Newswires Live
·
Aug 12

CarGurus is Maintained at Outperform by Oppenheimer

Dow Jones
·
Aug 12

Tarsus Pharmaceuticals Price Target Raised to $100.00/Share from $97.00 by Oppenheimer

Dow Jones
·
Aug 12

Snowflake Core Consumption Seen Supporting Upcoming Fiscal Q2 Results, Oppenheimer Says

MT Newswires Live
·
Aug 12

MongoDB is Maintained at Outperform by Oppenheimer

Dow Jones
·
Aug 12